Abstract
As the most common cancer in humans, basal cell carcinomas (BCCs) affect approximately 2.8 million people. Depending on the location, size, tumor subtype, and other factors, treatment may include topical therapy with imiquimod or 5-fluorouracil, cryotherapy, radiation, photodynamic therapy, electrodesiccation and curettage, surgical excision, and Mohs micrographic surgery, the latter of which has the lowest 5-year recurrence rate: between 0.7% and 2.4%. BCC is mainly a localized neoplasm, although less commonly, it can become locally advanced or even metastatic (0.0028–0.55%). Locally advanced BCC (laBCC) and metastatic BCC (mBCC) are both considered advanced BCC
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
